Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

NCT02637973 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Non-alcoholic Fatty Liver Disease

Interventions

DRUG: Empagliflozin
DRUG: Placebo

Sponsor

The Deutsche Diabetes Forschungsgesellschaft e.V.

Collaborators

[object Object]